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The paraoxonase 1 (PON1) gene polymorphisms in coronary
artery disease in the southeastern Turkish population
Abdussemet HAZAR1, Fuat DİLMEÇ2, Mustafa GÖZ1, Aydemir KOÇARSLAN1, Mehmet Salih AYDIN1,
Abbas Heval DEMİRKOL1

Aim: To investigate the association between the paraoxonase 1 (PON1) c.163T>A and c.575A>G polymorphisms
and coronary artery disease (CAD), and whether specific polymorphisms in the PON1 gene are associated with CAD
in the southeastern Turkish population. Many different genetic and clinical factors have been identified as causes or
contributors to atherosclerosis. Complex diseases such as CAD, hypertension, and diabetes are usually caused by an
individual’s susceptibility to various genes, environmental factors, and the interactions between them. The PON1
enzyme has been implicated in the pathogenesis of atherosclerosis and CAD.
Materials and methods: Enrolled in this study were 61 patients with CAD and 103 healthy individuals; their DNA
was isolated. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used
to determine the frequencies of the PON1 gene (NM_000446.5, GI: 5444) c.163T>A (Hsp92IIT>A) and c.575A>G
(AlwIA>G) polymorphisms in CAD cases.
Results: Our data indicated that the body mass index (BMI) (27.5 ± 5.7), low-density lipoprotein (LDL-C) values (127.0
± 45.8), and frequencies of diabetes (13.0) and hypertension (35.0) were significantly higher in CAD patients than in the
control subjects (25.9 ± 4.1; 105.6 ± 26.3; 2.0; and 19.0, respectively) (P < 0.05). No significant differences were observed
in the frequencies of the c.163T>A and c.575A>G genotypes of the PON1 gene in CAD patients compared to healthy
individuals (P > 0.05).
Conclusion: The PON1 gene c.163T>A and c.575A>G polymorphisms did not represent an important risk factor for
this disease in the southeastern Turkish population.
Key words: PON1 gene, polymorphism, coronary artery disease, PCR, RFLP

Güneydoğu Türk toplumunda koroner arter hastalığında paraoxonaz (PON1) geni
polimorfizmleri
Amaç: Arteriyoskleroze sebep veya katkı yapan birçok farklı genetik ve kliniksel faktör, tanımlanmıştır. Koroner arter
hastalığı (KAH), hipertansiyon ve diyabet gibi karmaşık hastalıklar, çoğunlukla çeşitli genler, çevresel faktörler ve bunlar
arasındaki etkileşimlerin bireysel duyarlılığı sonucu oluşurlar. Paraksonaz 1 (PON1) enzimi, aterosklerozis ve KAH’ın
patojenezinde rol oynar. Bu çalışmanın amacı, PON1 geni c.163T>A ve c.575A>G polimorfizmleri ile KAH arasındaki
ilişkiyi araştırmak ve Güneydoğu Türk toplumunda PON1 geni özel polimorfizmleri ile KAH arasında ilişkinin olup
olmadığını belirlemektir.
Yöntem ve gereç: Çalışmaya KAH’lı 61 hasta ile sağlıklı 103 birey dahil edildi ve bunların DNA’ları elde edildi. KAH
vakalarında PON1 geni (NM_000446.5, GI: 5444) c.163T>A (Hsp92IIT>A) ve c.575A>G (AlwIA>G) polimorfizm
sıklıklarının belirlenmesinde polimeraz zincir reaksiyonu-restriksiyon parça uzunluk polimorfizmi (PCR-RFLP)
tekniği kullanıldı.
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Bulgular: Sonuçlarımız, vücut kitle indeksi (BMI) (27,5 ± 5,7), düşük-yoğunluklu lipoprotein (LDL-C) (127,0 ± 45,8),
diyabet (13,0) ve hipertansiyon (35,0) sıklıklarının KAH’lı hastalarda kontrol bireylerine (sırasıyla 25,9 ± 4,1; 105,6 ±
26,3; 2,0; ve 19,0) göre anlamlı şekilde yüksek olduğunu gösterdi (P < 0,05). KAH’lı hastaların PON1 geni c.163T>A ve
c.575A>G genotip sıklıkları, sağlıklı bireylerle karşılaştırıldığında herhangi bir anlamlı farklılık bulunmadı (P > 0.05).
Sonuç: PON1 geni c.163T>A ve c.575A>G polimorfizmleri, güneydoğu Türk toplumunda bu hastalık için önemli bir
risk faktörü göstermedi.
Anahtar sözcükler: PON1 geni, polimorfizm, koroner arter hastalığı, PCR, RFLP

Introduction
Coronary artery disease (CAD) is a common and
complex disorder, and it has become a major source
of morbidity and mortality in different parts of the
world (1). Among genetic factors, the gene encoding
human paraoxonase 1 (PON1) has been implicated in
conferring genetic susceptibility to CAD (2).
Genetic polymorphisms that affect PON1 could
be predisposing risk factors both in environmental
toxicology and in cardiovascular diseases. Human
PON1 has 2 genetic polymorphisms giving rise to
amino acid substitutions at positions 55 (c.163T>A)
and 192 (c.575A>G). The c.575A>G polymorphism
is the major determinant of the PON1 activity against
organophosphates. The c.163T>A polymorphism
also modulates its activity (3).
The paraoxonase (PON) gene family in mammals
includes at least 3 members: PON1, PON2, and PON3
(4). The 3 PON genes share about 65% similarity at
the amino acid level and are located adjacent to each
other on chromosome 7 (7q21.3) in humans (5).
Both PON2 and PON3 possess antioxidant properties
and lactonase activity, but unlike PON1, they lack the
paraoxon or phenyl acetate-hydrolyzing activity (6).
The PON1 gene has 2 common polymorphisms in the
coding region, which lead to a glutamine-to-arginine
substitution at position c.575A>G and a leucineto-methionine substitution at position c.163T>A.
Both independently influence PON1 activity and
have been referred to as the molecular basis for this
interindividual variability (7).
CAD has a multifactorial etiology involving
physiological, environmental, and genetic factors,
leading to increased susceptibility (8). More recently,
there have been many studies investigating the
association between the PON1 gene polymorphisms
and CAD. However, the results are controversial. A
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great number of studies suggest that there is not an
association between the genotype and allele of the
PON1 gene c.163T>A polymorphic site and CAD,
as observed in different populations (9-16). On the
other hand, some other studies show an association
between CAD and the c.163T>A polymorphisms of
the PON1 gene in various populations (17-22).
Additionally, some studies reported that the
PON1 c.575A>G polymorphism does not represent
a risk factor for CAD (9,13-17,19-21,23). In parallel,
others report that this same polymorphic site is an
important risk factor for CAD (10,11,18,24-26).
Ex vivo, the PON1 polymorphisms are important
in determining the capacity of high-density
lipoprotein (HDL) to protect low-density lipoprotein
(LDL) against oxidative modification in vitro, which
may explain the relationship between the PON1
alleles and coronary heart disease in case-control
studies (3). The coding region polymorphisms
c.163T>A and c.575A>G of the PON1 gene showed
no association with HDL (27).
The aim of this study was to investigate whether
PON1 polymorphisms are important risk factors of
CAD in the southeastern Turkish population.
Materials and methods
Subjects and DNA extraction
This study was designed in Şanlıurfa Province in
the southeastern Anatolia region of Turkey between
September 2008 and August 2009.
Enrolled in this study were 61 patients with CAD
(18 females, mean age: 62.8 ± 8.4; and 43 males, mean
age: 62.6 ± 9.4) who had 1 or more coronary lesions
causing ≥50% stenosis, from the Regional Referral
Hospital of Harran University. Randomly selected
from blood donors were 103 healthy controls (50
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females, mean age: 33.0 ± 10.3; and 53 males, mean
age: 32.5 ± 9.9) who did not have any diseases or
clinical evidence of CAD or other disorders in the
family history of their first-degree relatives.

Separately digested was 10 μL of PCR product in
a 30-μL volume for c.163T>A and c.575A>G with 2
U of Hsp92II and AlwI (Fermentas), respectively, at
37 °C for 2 h.

Detailed demographic information, including
anthropometric measurements, cardiovascular risk
factors, and medication use, were recorded for all
participants. Body mass index (BMI) was calculated
as weight in kilograms divided by the square of height
in meters (kg/m2). The levels of triglyceride (TG),
total cholesterol (TC), HDL-cholesterol (HDL-C),
and LDL-cholesterol (LDL-C) were determined using
commercially available assay kits with an Abbott
Aeroset autoanalyzer (Abbott®, Illinois, USA).

The digested PCR products were separated on
3% agarose gel and analyzed using the Alpha Imager
System (Alpha Innotech, San Leandro, California,
USA). The digested PON1 c.163 T allele yielded
1 fragment of 171 bp, and the A allele yielded 2
fragments of 127 and 44 bp (Figure 1). The c.575 A
allele yielded 1 fragment of 99 bp, and the G allele
yielded 2 fragments of 63 and 36 bp (Figure 2).

We matched the CAD patients and healthy
controls for age and sex. EDTA-blood was taken from
these individuals, and genomic DNA was extracted
from whole blood leukocytes using the standard
salting-out procedure (28).

Student’s t-test and chi-square test were used
to determine differences in the means of the
demographic and clinical profiles. Genotype and
allele frequencies of PON1 c.163T>A and c.575A>G
were tested for Hardy-Weinberg equilibrium by
employing the chi-square test. Genotype and allele
frequencies of these polymorphisms were analyzed
with Fisher’s exact test. Statistical significance was
defined as P < 0.05.

Polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) technique
The c.163T>A (g.12801T>A, rs854560, PON1 55)
and c.575A>G (g.34650T>C, g.21439A>G, PON1
192) polymorphic sites of the PON1 (NM_000446.5;
GI: 5444) gene were investigated using the PCRRFLP technique. The PCR reactions were performed
in 10 mL of reaction volume, including 1× PCR
buffer, 2 mM MgCl2, 0.2 mM of each deoxynucleotide
triphosphate (dNTPs; Fermentas, St. Leon-Rot,
Germany), 0.2 μM of each primer (Table 1) (29) (Bio
Basic Inc., Ontario, Canada), 30 ng of DNA, and 0.5
U of Taq DNA polymerase (Fermentas). The PCR
program for these 2 polymorphic sites was performed
at 94 °C for 3 min (initial denaturation), 30 cycles,
with 94 °C for 30 s, 58 °C and 63 °C (c.163T>A and
c.575A>G, respectively) for 30 s, 72 °C for 40 s, and
72 °C for 5 min (final extension).

Statistical analysis

Ethics
Informed consent was obtained from all patients
before they were recruited to the study. The study was
approved by the Institutional Ethics Committee of
Harran University.
Results
The baseline characteristics of the patients and
controls are presented in Table 2. The patients in the
CAD group were older than the healthy controls (P =
0.001). The BMI, LDL-C, and prevalence of diabetes
and hypertension were significantly higher in the
CAD group than in the healthy subjects (P = 0.039, P

Table 1. Primer sequences used in this study.
PON1 gene SNPs

Primer sequences

PCR products (bp)

c.163T>A

5’-GAAGAGTGATGTATAGCCCCAG-3’
5’-TTTAATCCAGAGCTAATGAAAGCC-3’

171

c.575A>G

5’-TATTGTTGCTGTGGGACCTGAG-3’
5’-CACGCTAAACCCAAATACATCTC-3’

99
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M

1

2

3

4
M

1

2

3

4

99bp

171bp
200bp

200bp

100bp

100bp

63bp

124bp

36bp

44bp

Figure 1. The restriction profile of the PON1 gene Hsp192II
(c.163T>A). Lane M: DNA marker (100-1500 bp, Bio
Basic Inc., Canada); lane 1: undigested PCR product;
lane 2: TT genotype (homozygous, wild-type); lane
3: TA genotype (heterozygous); lane 4: AA genotype
(homozygous, polymorphic).

Figure 2. The restriction profile of the PON1 gene AlwI
(c.575A>G). Lane M: DNA marker (100-1500 bp, Bio
Basic Inc., Canada); lane 1: undigested PCR product;
lane 2: AA genotype (homozygous, wild-type); lane
3: AG genotype (heterozygous); lane 4: GG genotype
(homozygous, polymorphic).

Table 2. The demographic parameters in the patients with CAD and the control group.
CAD patients
(n = 61)

Controls
(n = 103)

P-value

43/18

50/53

0.017

Age (years)

62.6 ± 9.1

32.7 ± 10.0

0.001

BMI (kg/m2)

27.5 ± 5.7

25.9 ± 4.1

0.039

TG (mg/dL)

153.2 ± 63.5

168.7 ± 47.5

0.079

HDL-C (mg/dL)

37.6 ± 12.7

38.0 ± 9.3

0.797

LDL-C (mg/dL)

Gender (M/F)

127.0 ± 45.8

105.6 ± 26.3

0.001

Diabetes

13

2

0.001

Smoking

10

17

0.985

Hypertension

35

19

0.001

Values are mean ± standard deviation, M: male, F: female.

= 0.001, P = 0.001, and P = 0.001, respectively), while
there were no statistically significant differences
in TG, HDL-C, or prevalence of current cigarette
smoking (P = 0.079, P = 0.797, and P = 0.985,
respectively).
The genotype frequencies observed for the
c.163T>A and c.575A>G polymorphisms among this
study population did not differ significantly from those
expected under the Hardy-Weinberg equilibrium (P >
898

0.05). For the c.163 polymorphism, although the AA
genotype (16.4%) and A allele (43.4%) frequencies in
the CAD individuals were higher than those in the
healthy individuals (12.6%, and 36.4%, respectively),
these differences were not significant (P = 0.501).
Furthermore, there was no significant difference
between CAD patients and healthy controls for the
c.575 GG genotype (13.1% vs. 12.6%) and G allele
(36.1% vs. 36.9%) frequencies (Table 3).
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Table 3. PON1 gene polymorphisms in a Turkish population with CAD and the control group.
SNP
genotype/allele

CAD patients
(n = 61)

Healthy controls
(n = 103)

c.163T>A
Genotypes
TT
TA
AA

18 (29.5%)
33 (54.1%)
10 (16.4%)

Alleles
T
A

X2

OR (95% CI)

P-value

41 (39.8%)
49 (47.6%)
13 (12.6%)

0.653
0.452

Reference
1.299 (0.688-2.451)
1.357 (0.556-3.316)

0.419
0.501

69 (56.6%)
53 (43.4%)

131 (63.6%)
75 (36.4%)

1.594

Reference
1.342 (0.850-2.119)

0.126

c.575A>G
Genotypes
AA
AG
GG

25 (41.0%)
28 (45.9%)
8 (13.1%)

40 (38.8%)
50 (48.5%)
13 (12.6%)

0.107
0.008

Reference
0.899 (0.477-1.697)
1.045 (0.407-2.685)

0.435
0.553

Alleles
A
G

78 (62.3%)
44 (36.1%)

130 (63.1%)
76 (36.9%)

0.023

Reference
0.865 (0.606-1.537)

0.488

Abbreviations: CAD = coronary artery disease, X2 = chi-squared, OR = odds ratio, CI = confidence interval, SNP =
single nucleotide polymorphism.

On one hand, there was no significant difference
between CAD patients with (AA) or without (TT,
wild-type) the polymorphic genotype in terms of age,
BMI, TG, HDL-C, LDL-C, diabetes, current cigarette
smoking, and hypertension for the c.163T>A
polymorphism (P > 0.05). On the other hand, there

was a statistically significant difference between
CAD patients with (GG) or without (AA, wild-type)
the polymorphic genotype in terms of hypertension
prevalence for the c.575A>G polymorphism (P <
0.05), except for age (Table 4).

Table 4. The demographic and clinical profiles with and without polymorphic genotype for the PON1 gene in patients
with CAD.
c.163T>A
Genotype
Subjects (n)
Age (years)
BMI (kg/m2)
TG (mg/dL)
HDL-C (mg/dL)
LDL-C (mg/dL)
Diabetes
Smoking
Hypertension

TT
18
63.4 ± 7.7
26.7 ± 6.0
159.9 ± 69.9
40.2 ± 15.0
124.8 ± 42.4
2
3
12

AA
10
63.8 ± 8.1
29.0 ± 9.0
145.3 ± 58.8
38.6 ± 15.2
119.5 ± 27.3
1
2
5

c.575A>G
P-value
0.895
0.788
0.580
0.758
0.724
0.927
0.825
0.387

AA
25
59.9 ± 8.6
27.9 ± 6.2
148.4 ± 62.1
37.9 ± 13.6
132.5 ± 52.3
6
7
15

GG
8
68.7 ± 4.8
28.1 ± 5.8
115.0 ± 52.9
41.3 ± 22.7
107.0 ± 29.3
1
0
4

P-value
0.011
0.962
0.182
0.618
0.201
0.429
0.076
0.447

Values are mean ± standard deviation; TT (Hsp92II) and AA (AlwI) genotypes: wild-types, not polymorphic; AA
(Hsp92II) and GG (AlwI) genotypes: polymorphic.
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Discussion
CAD is the leading cause of mortality worldwide
(2). A great number of previous studies have provided
evidence to propose that the PON1-c.163T>A (at
position 55) and PON1-c.575A>G (at position 192)
polymorphisms may be associated with CAD risk in
the general population, due to the PON1 enzyme’s
role in lipid metabolism (11). Atherosclerosis is a
progressive disease characterized by the accumulation
of lipids and fibrous elements in the large arteries (6).
However, the genetic factors underlying this form of
cardiovascular disease are complex and not clearly
established (17).
Upon investigating the effects of 2 exonic
polymorphic sites of the PON1 gene on CAD risk
in the southeastern Turkish population, we did not
establish any association of the PON1 c.163T>A
and c.575A>G genotypes and alleles with CAD.
Although the frequencies of the c.163 AA genotype
(16.4%) and A allele (43.4%) in CAD patients were
higher than those in healthy subjects (12.6% and
36.4%, respectively), we did not find any significant
difference when CAD patients were compared with
healthy individuals (P > 0.05). Similarly, we did
not observe any association between CAD and the
frequencies of the PON1 c.575 GG genotype and
G allele (P > 0.05). Although several studies on its
association with cardiovascular diseases have been
performed, inconsistent results have been obtained
from different populations. We here, however, did
not determine an association with sex in either study
group (data not shown).
Hong et al. in a Japanese population (9), Allebrandt
et al. in a Euro- and an Afro-Brazilian population
(10), Agrawal et al. in an Indian population (11),
Arca et al. in an Italian population (12), Mackness
et al. in a British population (13), Cascorbi et al.
in a German population (14), Mendonça et al. in a
Portuguese population (15), and Thyagarajan et al. in
an American population (16) showed that genotype
distributions and allele frequencies of the c.163T>A
polymorphism were not significantly different
between control subjects and patients. However,
Oliveira et al. in a Brazilian population (17); Özkök
et al. (18), Taşkiran et al. (19), and Kaman et al.
(20) in Turkish populations; Chi et al. in a Chinese
population (21), and Malin et al. in a Finnish (23)
900

population showed that genotype distributions and
allele frequencies of the c.163T>A polymorphism
were significantly different between control subjects
and patients.
On the other hand, Hong et al. in a Japanese
population (9); Mackness et al. in British population
(13); Cascorbi et al. in a German population (14);
Mendonça et al. in a Portuguese population (15);
Thyagarajan et al. (16) in an American population;
Oliveira et al. in a Brazilian population (17); Taşkiran
et al. (19), Kaman (20), and Aynacioglu (22) in Turkish
populations; and Malin et al. in a Finnish population
(23) showed that genotype distributions and allele
frequencies of the c.575A>G polymorphism were not
significantly different between control subjects and
patients. Additionally, Allebrandt et al. in a Euroand Afro-Brazilian population (10), Agrawal et al. in
an Indian population (11), Özkök et al. in a Turkish
population (18), Gluba et al. in a Polish population
(24), and Mohamed et al. in an Egyptian (26)
population showed that genotype distributions and
allele frequencies of the c.575A>G polymorphism
were significantly different between control subjects
and patients.
When the allele frequencies were analyzed
separately according to gender, age, cigarette smoking,
and hyperlipidemia, there was still no statistically
significant difference for either polymorphism.
Although there has been some controversy about
the relationship between PON1 polymorphisms and
CAD, our findings were similar to those of several
previous reports (9-17,19-21,23). The inconsistent
association of PON1 with CAD may be attributed
to factors that are different between studies,
including ethnic and environmental factors, and
methodological factors such as sampling scheme and
trial size. Among these factors, the most notable is the
fact that allele frequencies of the 2 polymorphisms do
vary between different ethnic groups.
In the comparison of CAD patients without (TT,
wild-type) and with (AA) polymorphic genotypes for
the c.163T>A polymorphism, there was no significant
difference in terms of age, BMI, TG, HDL-c,
LDL-c, diabetes, smoking, and hypertension (P >
0.05). However, we found a statistically significant
difference between patients without (AA genotype,
wild-type) and with (GG) the polymorphic genotype
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in terms of average age (59.9 ± 8.6 vs. 68.7 ± 4.8) for
the c.575A>G polymorphism in the southeastern
Turkish population. The ages of the patients with
the GG genotype (Arg) were higher than in patients
with AA genotypes (Glu). A number of studies have
shown that the c.575 GG homozygotes have been
found to have further loss in enzyme activity with
age (30,31). In order to confirm this result, it would
be useful to investigate the difference between the
PON1 gene expression levels in young and old CAD
patients with the c.575 GG genotype. Additionally,
we did not correlate between healthy controls with
or without polymorphic genotypes for the c.163T>A
and c.575A>G (data not shown).
The PONs prevent LDL-C from peroxidation,
thereby preventing atherosclerosis. The PON1 is
exclusively associated with HDL-C, and its antioxidant
activity is largely attributed to the PON1 located on it (6).
The PON1 genotype clearly determined the oxidative
modification of lipoproteins and may have played a role
in the pathogenesis of atherosclerosis via its protective
effect against lipoprotein oxidation in Japanese subjects
(32). It has been shown that PON1 activity inversely
relates to CAD risk, but is not independent of HDL due
to its close association with HDL particles. These data

strongly suggest that low PON1 activity is not a causal
factor for atherogenesis (33).
Our data indicated that gender, age, BMI, LDL-C,
diabetes, and hypertension were significantly higher
in the CAD group than in the healthy subjects, while
there were no statistically significant differences in
TG, HDL-C, and the prevalence of current cigarette
smoking. Our results were consistent with the data
reported previously (19,22).
We conclude that the PON1 gene c.163T>A
and c.575A>G polymorphisms do not represent
an important risk factor for this disease in the
southeastern Turkish population. However, studies
with higher numbers of patients and controls in
various populations will be required in order to
determine the influence of these and other candidate
genes and single nucleotide polymorphisms on the
risk of CAD.
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